🤑 It doesn’t get more affordable. Grab this 60% OFF Black Friday offer before it disappears…CLAIM SALE

Froome rejected TUE on 'moral' grounds

Published 06/01/2017, 23:26
Updated 06/01/2017, 23:30
© Reuters. Rider Chris Froome of Britain attends the presentation of the itinerary of the 2017 Tour de France cycling race during a news conference in Paris

LONDON (Reuters) - Three-times Tour de France champion Chris Froome has said he rejected a therapeutic use exemption (TUE) to treat his asthma during the 2015 edition of the race on moral grounds.

The Team Sky rider was granted TUEs in May 2013 and April 2014 to treat the condition but chose not to apply for a TUE - which allows athletes to take banned substances on medical grounds - when he was advised to do so during the 2015 Tour.

"I didn't feel having a TUE in the last week of the Tour was something I was prepared to do. It did not sit well morally with me," he told the BBC.

In 2013, Froome was allowed to use prednisolone for his asthma for a week before winning the Criterium du Dauphine while the following year he took it for a week during the Tour de Romandie, as he defended his title.

Bradley Wiggins and Team Sky have been under scrutiny since hacked medical records showed the Briton was granted TUEs for anti-inflammatory drug triamcinolone before the 2011 Tour de France, his 2012 Tour de France win and the 2013 Giro d'Italia.

There is no suggestion that Wiggins, Froome or Team Sky broke any rules.

"I think WADA (the World Anti-Doping Agency) need to tighten their regulations around TUEs, so they're not something that we question, their legitimacy," added Froome.

© Reuters. Rider Chris Froome of Britain attends the presentation of the itinerary of the 2017 Tour de France cycling race during a news conference in Paris

"It's not good for sport in general. The fact that we're discussing the validity of results, that brings it back to the authorities, it is something they need to tighten up on so that there aren't questions being asked anymore."

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.